Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement

Eva Van Braeckel^{1

2}, Iain Page³, Jesper Rømhild Davidsen^{4

5}, Christian B Laursen^{4

5}, Ritesh Agarwal⁶, Ana Alastruey-Izquierdo⁷, Aleksandra Barac^{8

9}, Jacques Cadranel¹⁰, Arunaloke Chakrabarti¹¹, Oliver A Cornely^{12

13

14

15}, David W Denning¹⁶, Holger Flick¹⁷, Jean-Pierre Gangneux¹⁸, Cendrine Godet¹⁹, Yuta Hayashi²⁰, Christophe Hennequin²¹, Martin Hoenigl^{22

23}, Muhammed Irfan²⁴, Koichi Izumikawa^{25

26}, Won-Jun Koh²⁷, Chris Kosmidis^{16

28}, Christoph Lange^{29

30

31

32}, Bernd Lamprecht³³, Francois Laurent³⁴, Oxana Munteanu³⁵, Rita Oladele³⁶, Thomas F Patterson³⁷, Akira Watanabe³⁸, Helmut J F Salzer³⁹; CPAnet

Affiliations

¹ Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
² Dept of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
³ Regional Infectious Diseases Unit, NHS Lothian, Western General Hospital, Edinburgh, UK.
⁴ Pulmonary Aspergillosis Centre Denmark (PACD), Dept of Respiratory Medicine, Odense University Hospital, Odense, Denmark.
⁵ Odense Respiratory Research Unit (ODIN), Dept of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁶ Dept of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
⁷ Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
⁸ Clinic for Infectious and Tropical Diseases, University Clinical Centre of Serbia, Belgrade, Serbia.
⁹ Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
¹⁰ Dept of Pulmonology and Thoracic Oncology, APHP Hôpital Tenon and Sorbonne University, Paris, France.
¹¹ Dept of Medical Microbiology; Center of Advanced Research in Medical Mycology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
¹² University of Cologne, Faculty of Medicine and University Hospital Cologne, Dept I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany.
¹³ University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
¹⁴ University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany.
¹⁵ German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
¹⁶ Manchester Fungal Infection Group, University of Manchester, Manchester, UK.
¹⁷ Division of Pulmonology, Dept of Internal Medicine, Medical University of Graz, Graz, Austria.
¹⁸ Dept of Parasitology and Mycology, Centre Hospitalier Universitaire de Rennes, Rennes, France.
¹⁹ Dept of Pulmonology, AP-HP, Hôpital Bichat, Paris, France.
²⁰ Dept of Respiratory Medicine, Higashinagoya National Hospital, Nagoya, Japan.
²¹ Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, Paris, France.
²² Division of Infectious Diseases and Global Health, University of California San Diego, La Jolla, CA, USA.
²³ Division of Infectious Diseases, Dept of Internal Medicine, Medical University of Graz, Graz, Austria.
²⁴ Section of Pulmonary and Critical Care Medicine, Dept of Medicine, Aga Khan University, Karachi, Pakistan.
²⁵ Dept of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
²⁶ Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan.
²⁷ Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
²⁸ National Aspergillosis Centre, Manchester University NHS Foundation Trust, Manchester, UK.
²⁹ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
³⁰ German Center for Infection Research (DZIF), DZIF Partner Site, Hamburg-Lübeck-Borstel-Riems, Germany.
³¹ International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
³² Dept of Medicine, Karolinska Institute, Stockholm, Sweden.
³³ Dept of Pulmonology, Kepler University Hospital, Linz, Austria.
³⁴ Dept of Cardiothoracic Imaging, Hôpital du Haut Lévêque, CHU de Bordeaux, Pessac, France.
³⁵ Division of Pneumology and Allergology, Dept of Internal Medicine, State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau, Republic of Moldova.
³⁶ Dept of Microbiology, College of Medicine, University of Lagos, Lagos, Nigeria.
³⁷ San Antonio Center for Medical Mycology, Division of Infectious Diseases, The University of Texas Health Science Center, San Antonio, TX, USA.
³⁸ Medical Mycology Research Center, Chiba University, Chiba, Japan.
³⁹ Dept of Pulmonology, Kepler University Hospital, Linz, Austria helmut.salzer@kepleruniklinikum.at.

PMID: 35236726
DOI: 10.1183/13993003.02950-2021

Free article

Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement

Eva Van Braeckel et al. Eur Respir J. 2022.

Free article

. 2022 Jun 9;59(6):2102950.

doi: 10.1183/13993003.02950-2021. Print 2022 Jun.

Authors

Affiliations

¹ Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
² Dept of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
³ Regional Infectious Diseases Unit, NHS Lothian, Western General Hospital, Edinburgh, UK.
⁴ Pulmonary Aspergillosis Centre Denmark (PACD), Dept of Respiratory Medicine, Odense University Hospital, Odense, Denmark.
⁵ Odense Respiratory Research Unit (ODIN), Dept of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁶ Dept of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
⁷ Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
⁸ Clinic for Infectious and Tropical Diseases, University Clinical Centre of Serbia, Belgrade, Serbia.
⁹ Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
¹⁰ Dept of Pulmonology and Thoracic Oncology, APHP Hôpital Tenon and Sorbonne University, Paris, France.
¹¹ Dept of Medical Microbiology; Center of Advanced Research in Medical Mycology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
¹² University of Cologne, Faculty of Medicine and University Hospital Cologne, Dept I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany.
¹³ University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
¹⁴ University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany.
¹⁵ German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
¹⁶ Manchester Fungal Infection Group, University of Manchester, Manchester, UK.
¹⁷ Division of Pulmonology, Dept of Internal Medicine, Medical University of Graz, Graz, Austria.
¹⁸ Dept of Parasitology and Mycology, Centre Hospitalier Universitaire de Rennes, Rennes, France.
¹⁹ Dept of Pulmonology, AP-HP, Hôpital Bichat, Paris, France.
²⁰ Dept of Respiratory Medicine, Higashinagoya National Hospital, Nagoya, Japan.
²¹ Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, Paris, France.
²² Division of Infectious Diseases and Global Health, University of California San Diego, La Jolla, CA, USA.
²³ Division of Infectious Diseases, Dept of Internal Medicine, Medical University of Graz, Graz, Austria.
²⁴ Section of Pulmonary and Critical Care Medicine, Dept of Medicine, Aga Khan University, Karachi, Pakistan.
²⁵ Dept of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
²⁶ Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan.
²⁷ Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
²⁸ National Aspergillosis Centre, Manchester University NHS Foundation Trust, Manchester, UK.
²⁹ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
³⁰ German Center for Infection Research (DZIF), DZIF Partner Site, Hamburg-Lübeck-Borstel-Riems, Germany.
³¹ International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
³² Dept of Medicine, Karolinska Institute, Stockholm, Sweden.
³³ Dept of Pulmonology, Kepler University Hospital, Linz, Austria.
³⁴ Dept of Cardiothoracic Imaging, Hôpital du Haut Lévêque, CHU de Bordeaux, Pessac, France.
³⁵ Division of Pneumology and Allergology, Dept of Internal Medicine, State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau, Republic of Moldova.
³⁶ Dept of Microbiology, College of Medicine, University of Lagos, Lagos, Nigeria.
³⁷ San Antonio Center for Medical Mycology, Division of Infectious Diseases, The University of Texas Health Science Center, San Antonio, TX, USA.
³⁸ Medical Mycology Research Center, Chiba University, Chiba, Japan.
³⁹ Dept of Pulmonology, Kepler University Hospital, Linz, Austria helmut.salzer@kepleruniklinikum.at.

PMID: 35236726
DOI: 10.1183/13993003.02950-2021

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: R. Agarwal has received grants from Cipla Pharmaceuticals, India outside the submitted work. A. Alastruey-Izquierdo has received honoraria for lectures from Gilead and Pfizer. O.A. Cornely reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; payment for expert testimony from Cidara; participation on a data safety monitoring board or advisory board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI, Shionogi; a pending patent currently reviewed at the German Patent and Trade Mark Office; other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley. D.W. Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; acts or has recently acted as a consultant to Pulmatrix, Pulmocide, Zambon, Biosergen, TFF Pharmaceuticals, Bright Angel Therapeutics and Cipla; sits on the DSMB for a SARS-CoV-2 vaccine trial; honoraria for talks from Hikma, Gilead, BioRad, Basilea, Mylan and Pfizer; he is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group. H. Flick participated in the past 3 years on advisory boards from Boehringer Ingelheim and INSMED and has received honoraria for lectures and travel support from Boehringer Ingelheim, MSD, Roche, Novartis, AstraZeneca, GSK, Chiesi, Pfizer and GSK. C. Godet has received honoraria for lectures and travel support from Pfizer and MSD; fees for board memberships from SOS Oxygène and Pulmatrix; grant support from Ohre Pharma, Boehringer Ingelheim, Pfizer, MSD, SOS Oxygène, ISIS Medical, Vivisol, Elivie, CF Sante, Oxyvie LVL Medicaland and AstraZeneca; grant to the University of Poitiers from the French Ministry of Health for NEBULAMB and CPAAARI clinical trial. C. Hennequin has received funds for basic research from MSD; received travel grants from Pfizer and Gilead and has received honoraria for talks by Gilead. M. Hoenigl has received research funds from NIH, Gilead, Euroimmune, Astellas, Pfizer, F2G and MSD. K. Izumikawa has received research funds and speakers’ honoraria from Astellas Pharma Inc., Pfizer Japan Inc., MSD K.K. a subsidiary of Merck & Co., Inc., Asahi Kasei Pharma Cooperation and Sumitomo Dainippon Pharma Co., Ltd. C. Lange has received honoraria for talks from Chiesi, Gilead, Novartis, Oxfordimmunotec, Janssen and Insmed. T.F. Patterson has received grant support to UT Health San Antonio from Cidara, F2G and Gilead and was a consultant or served on data review committees for Appili, Basilea, Mayne, Merck, Pfizer, Scynexis and Sfunga. A. Watanabe has received research funding from Shionogi & Co. Ltd. and Eiken Chemical Co. Ltd. E. van Braeckel, I. Page, J.R. Davidsen, C.B. Laursen, A. Barac, J. Cadranel, J.P. Gangneux, Y. Hayashi, M. Irfan, W.J. Koh, C. Kosmidis, B. Lamprecht, F. Laurent, O. Munteanu, R. Oladele, A. Chakrabarti and H.J.F. Salzer have no conflict of interest.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement

Affiliations

Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement

Authors

Affiliations

Conflict of interest statement

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources